Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. - Wikidata - awgldk - TriplyDB

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

http://www.wikidata.org/entity/Q53583746

about

Treatment of light chain deposition disease with bortezomib and dexamethasone Current Trends of Renal Impairment in Multiple Myeloma Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment.Bortezomib in patients with renal impairment.Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma Update on the optimal use of bortezomib in the treatment of multiple myeloma Case report on renal failure reversal in lambda chain multiple myeloma with bortezomib and dexamethasone.Complete remission of lambda light chain myeloma presenting with acute renal failure following treatment with bortezomib and steroids Late recurrence of light chain deposition disease after kidney transplantation treated with bortezomib: a case report Bortezomib in the management of multiple myeloma.Percentage of urinary albumin excretion and serum-free light-chain reduction are important determinants of renal response in myeloma patients with moderate to severe renal impairment.Proteasome inhibitors in the treatment of multiple myeloma Immunoglobulin light chains activate nuclear factor-κB in renal epithelial cells through a Src-dependent mechanism.Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.The use of novel agents in the treatment of relapsed and refractory multiple myeloma Renal complications in multiple myeloma and related disorders: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis.Survival from multiple myeloma in England and Wales up to 2001.European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial.Lenalidomide in combination with dexamethasone in elderly patients with advanced, relapsed or refractory multiple myeloma and renal failure.Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis.Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens.Bortezomib in the front-line treatment of multiple myeloma.Treatment of relapsed and refractory myeloma.Initial therapy in multiple myeloma: investigating the new treatment paradigm.Kidney disease associated with plasma cell dyscrasias Guidelines for the diagnosis and management of multiple myeloma 2011.A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence?Bortezomib for previously untreated multiple myeloma.Bortezomib for previously untreated multiple myeloma.Management of myeloma-associated renal dysfunction in the era of novel therapies.Novel approaches for reducing free light chains in patients with myeloma kidney.Current treatments for renal failure due to multiple myeloma.Kidney disease and multiple myeloma.Current strategies for treatment of relapsed/refractory multiple myeloma.

P2860

Q24658325-DA92EBEE-9BC2-4E02-9797-D7A136EAE725 Q26740444-D7A65048-AE1A-4833-9542-F8DDEA117B8A Q30595175-24A7D7A6-E215-4AA0-A065-39309A7B0CC9 Q33376918-37CB01DD-43B1-47F9-879C-BB486DD3C9DD Q33396250-0D57EBCC-9414-4563-967A-3BEADA3A79B3 Q33398587-B4938DC3-6D83-45DC-9ABD-2826A94EFF81 Q33400871-F6FBEDBB-C6DA-4CC9-8914-22C738A3D684 Q33405602-68352915-CF8E-47FE-A22E-536CF83D31EE Q33408056-A4392B00-C592-4194-B392-7BD186EB0559 Q33440007-BC46D084-4350-407A-BC3D-653A7005B012 Q33874209-39D7632C-D73E-4E0B-A670-2F63A1486AFB Q34096413-AC1E6C9E-93E9-4B69-9BDC-07A7474BC2E3 Q34228650-0C506011-7460-4204-9B7B-4C01843D6887 Q34418462-9F165F2F-B5AB-463F-94CB-068F756C2494 Q34448964-33B2D951-27D7-4247-9406-0E2DCEF2AF48 Q34611676-8B03C0D9-DFCD-4887-B581-7DDDF95C2F6B Q34666924-1B969E24-0F9A-408C-93B6-46E002848E84 Q35012436-1AFA09B9-5E91-43BF-A4BB-97E9530D351E Q35097319-C11B768D-6FD9-46A9-A415-F30E19B1C1DC Q36209159-8AD04DE5-C657-4EFD-A877-52216D1DABFC Q36686965-B6DC565C-CABC-428C-9A6D-EE4F391C2D86 Q36917738-9A25EB61-5D66-4404-A123-9E330B8D46E0 Q36930970-467E17CE-A099-4CF2-A587-52F9053603F4 Q36934144-D58FE823-ECF7-42D6-9BCD-58F4DC589365 Q37112901-B212B6D9-3FBC-4CD5-B76A-60DCA0DD51FD Q37152486-31D21981-25D8-45E8-9C99-2DA80FC95DB0 Q37157442-EFBA7E30-1130-467F-9761-0CF0F53E166E Q37202761-9EB412FE-30F6-4DF6-8FCE-72663018FFA6 Q37209929-F1519BEC-DEE0-4BFB-9C8B-8135F766E734 Q37411805-BE6E46CC-28F6-419C-A4EC-2DE142988A7C Q37750106-2547D374-F797-4184-997F-932B785A10AF Q37875193-5FB0766D-D86C-4AE9-88FF-6C489B97B567 Q37903590-0FB1D11B-2319-438B-BA19-DCD020993D0B Q37908155-4D961491-151D-4841-BC8F-7F42A1E41E68 Q37937699-DDD5EF0D-EEF9-4ADE-8C1D-1DA9055DE1D1 Q37978343-60784E86-5C5F-4F0C-B36F-DD16068D4DB7 Q37986358-A6713672-3202-4998-BCF3-61069442F4DA Q38109235-C6621BC9-1E20-41C9-9D29-2EA34A9BFC8E Q38122674-D1ECFC42-E4EC-45A3-A0B6-7BF5D2C48D3B Q38182683-EBCE54C5-510C-421A-951B-A1A09DA4A2FB

P2860

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

http://www.wikidata.org/entity/Q53583746

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Activity and safety of bortezo ...... lticenter retrospective study.

@en

Activity and safety of bortezo ...... lticenter retrospective study.

@nl

type

label

Activity and safety of bortezo ...... lticenter retrospective study.

@en

Activity and safety of bortezo ...... lticenter retrospective study.

@nl

prefLabel

Activity and safety of bortezo ...... lticenter retrospective study.

@en

Activity and safety of bortezo ...... lticenter retrospective study.

@nl

P1433

Q53583746-4035498C-7105-4892-A9F4-F8BADA561AFF

P1476

Q53583746-5CBB6B1D-8599-44ED-AAA4-907146AE64E2

P2093

Q53583746-074BA32D-09F9-4363-9D5D-3D65D3DC7B3C

Q53583746-136AC0A3-903C-435B-8408-D28FD17CCA05

Q53583746-29F3F442-4857-4645-9DDB-D3A978DB36DF

Q53583746-514AF160-7D44-4334-9812-7E3BD22EEB61

Q53583746-5EFE6B99-753F-4CAE-8EB6-AEE0E70DEF74

Q53583746-849DD3C2-758E-44E6-9BDF-E4686621164E

Q53583746-A6301A9C-0BDA-4960-AFBE-839C4CFEB463

Q53583746-DD2AF305-1668-4254-8FD4-13DC77C22E82

P304

Q53583746-C15DF1AF-6152-4DBD-8492-D0709C4FE7D2

P31

Q53583746-A7879CD5-FC46-4843-8566-B8504F067835

P356

Q53583746-BB4AD4B0-D587-4CBD-B72E-9ED5EDE3C49F

P407

Q53583746-6D59F299-FEC1-4000-80BC-B813D4FBCEF4

P433

Q53583746-547F77E4-60FD-4B02-8C00-FEFE4D3B3F4A

P478

Q53583746-F0610F4E-1E5A-499D-8F57-252A179A87BD

P50

Q53583746-35AEABFF-02AB-4DA6-BFFB-A6A6C785FDC5

Q53583746-37EE5586-278E-4F14-B586-C015668009C7

P577

Q53583746-961FB8EB-5393-4EE6-911D-725D5B51B964

P5875

Q53583746-06EC453C-A293-48C2-8ECB-BE0FC070D458

P698

Q53583746-704653F0-1F4F-4EB7-AD79-F02D295577AC

P921

Q53583746-DD2EFD22-76D6-4AA2-809C-49F90DEEE7AF

P356

BLOOD-2006-09-046409

P1433

P1476

Activity and safety of bortezo ...... lticenter retrospective study.

@en

P2093

Asher A Chanan-Khan

http://www.w3.org/2001/XMLSchema#string

Jayesh Mehta

http://www.w3.org/2001/XMLSchema#string

Jonathan L Kaufman

http://www.w3.org/2001/XMLSchema#string

Joseph Tariman

http://www.w3.org/2001/XMLSchema#string

Kena C Miller

http://www.w3.org/2001/XMLSchema#string

Nikhil C Munshi

http://www.w3.org/2001/XMLSchema#string

Robert Schlossman

http://www.w3.org/2001/XMLSchema#string

Seema Singhal

http://www.w3.org/2001/XMLSchema#string

P304

2604-2606

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2006-09-046409

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Paul G Richardson

P577

2006-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6659752

http://www.w3.org/2001/XMLSchema#string

P698

17138816

http://www.w3.org/2001/XMLSchema#string

P921